Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.44 |
| ▸ | TUBB | P07437 | 4/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.44 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.44 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25243568 | 0.85 | TUBB4A (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25282200 | 0.81 | TUBB4A (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL24110326 | 0.77 | TDO2 (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18247631 | 0.77 | CYP19A1 (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL24110316 | 0.76 | TUBB4A (0.33) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25436814 | 0.72 | NAPRT (0.36) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL21335595 | 0.71 | CYP19A1 (0.42) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL31359683 | 0.71 | HSP90AA1 (0.36) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31359719 | 0.71 | MAPT (0.35) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18258134 | 0.69 | CYP19A1 (0.37) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298003-B1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2023-04-19 | — | — | EP | disclosed |
| EP-3298003-B1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2023-04-19 | — | — | EP | disclosed |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-20200095227-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-26 | — | — | US | disclosed |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| US-20180297983-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-18 | — | — | US | disclosed |
| EP-3298003-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185279-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297983-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | PADI4, PADI1, PADI2 | TUBB4A 989/4885TUBB 2147/4885TUBA3C 3250/4885 |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | TUBB4A 989/4885TUBB 2147/4885TUBA3C 3250/4885 |
| US-20200095227-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | PADI4, PADI1, PADI2 | TUBB4A 989/4885TUBB 2147/4885TUBA3C 3250/4885 |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | TUBB4A 989/4885TUBB 2147/4885TUBA3C 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.